These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 1037379)
1. [Endocrine effects of bromocryptin in patients with Parkinsonism]. Barreca T; Gianrossi R; Gallamini A; Nizzo MC; Queirolo A Boll Soc Ital Biol Sper; 1976 Oct; 52(19):1564-7. PubMed ID: 1037379 [No Abstract] [Full Text] [Related]
2. [Treatment of Parkinson disease with Bromocriptine (CB 154 Sandoz) (author's transl)]. Jacobides GB; Audibert A Ther Umsch; 1975 Jul; 32(7):469-71. PubMed ID: 1105868 [No Abstract] [Full Text] [Related]
3. [Experience with the use of parlodel in the treatment of Parkinson patients]. Stoliarova LG; Kadykov AS; Shvedkov VV; Pivovarova VM Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(2):219-22. PubMed ID: 3705825 [TBL] [Abstract][Full Text] [Related]
4. [Treatment of Parkinson's disease with bromocriptine]. Castaigne P; Laplane D; Bousser MG; Bories F Nouv Presse Med; 1976 Apr; 6(17):1482. PubMed ID: 1037400 [No Abstract] [Full Text] [Related]
5. [Letter: Efficacy of bromocriptine in 2 cases of levodopa-resistant parkinsonism]. Kissel P; Andre JM; Jacquier A Nouv Presse Med; 1976 Jan; 5(4):210. PubMed ID: 1264671 [No Abstract] [Full Text] [Related]
6. Developments in the treatment of parkinsonism. Calne DB N Engl J Med; 1976 Dec; 295(25):1433-4. PubMed ID: 989886 [No Abstract] [Full Text] [Related]
8. Bromocriptine and lisuride in Parkinson disease. Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164 [TBL] [Abstract][Full Text] [Related]
9. [Parkinsonian syndrome caused by carbon monoxide poisoning. Preliminary results of the treatment with bromocriptine]. De Pooter MC; Leys D; Godefroy O; De Reuck J; Petit H Rev Neurol (Paris); 1991; 147(5):399-403. PubMed ID: 1853038 [TBL] [Abstract][Full Text] [Related]
11. Clinical studies with bromocriptine in idiopathic parkinsonism. Teychenne PF; Kartzinel R; Perlow M; Pfeiffer R; Calne DB Trans Am Neurol Assoc; 1976; 101():302-4. PubMed ID: 1037483 [No Abstract] [Full Text] [Related]
12. Letter: Growth-hormone response to bromocriptine in parkinsonism. Shaw KM; Lees AJ; Hayes S; Ross EJ; Stern GM; Thompson BD Lancet; 1976 Jan; 1(7952):194. PubMed ID: 54702 [No Abstract] [Full Text] [Related]
13. Psychiatric effects of bromocriptine and lergotrile in Parkinsonian patients. Serby M; Angrist B; Lieberman A Adv Biochem Psychopharmacol; 1980; 23():287-92. PubMed ID: 6104908 [No Abstract] [Full Text] [Related]
14. Lisuride in parkinsonism. Parkes JD; Schachter M; Marsden CD; Smith B; Wilson A Ann Neurol; 1981 Jan; 9(1):48-52. PubMed ID: 7212665 [TBL] [Abstract][Full Text] [Related]
15. Successful use of bromocriptine in the treatment of a patient with chronic portasystemic encephalopathy. Morgan MY; Jakobovits A; Elithorn A; James IM; Sherlock S N Engl J Med; 1977 Apr; 296(14):793-4. PubMed ID: 576493 [No Abstract] [Full Text] [Related]
16. [Oral lisuride in Parkinson's disease]. Obeso JA; Luquin MR; Martínez Lage JM Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822 [No Abstract] [Full Text] [Related]
18. [Bromocriptin in Parkinson's syndrome]. Völler GW; Ulm G Med Welt; 1979 Dec; 30(51-52):1930-3. PubMed ID: 542110 [No Abstract] [Full Text] [Related]
19. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Jackson JA; Jankovic J; Ford J Ann Neurol; 1983 Mar; 13(3):273-8. PubMed ID: 6847139 [TBL] [Abstract][Full Text] [Related]
20. Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists. Klawans HL; Paleologos N Clin Neuropharmacol; 1986; 9(3):298-302. PubMed ID: 3719575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]